EUVIMED · CrossrefZeitschrift
Clinical Ovarian Cancer
ISSN 1941-4390 · Elsevier BV
Neueste Artikel
Luteinized Fibroma of the Ovary With Minor Sex Cord Elements: An Incidental Finding
Isolated Myeloid Sarcoma of the Vulva
Outpatient Intraperitoneal Chemotherapy for All Stages of Ovarian, Fallopian Tube, and Peritoneal Cancers: A Pilot Study
Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma
The Efficacy and Toxicity of Bevacizumab in Combination With Gemcitabine in Patients With Recurrent Ovarian Cancer
Successful Treatment of Metastatic Squamous Cell Carcinoma of the Ovary Arising Within a Mature Cystic Teratoma
Spontaneous Renal Pelvis Rupture Due To Ovarian Carcinoma: Case Report
VEGF in the Development of Ovarian Malignancy
Metastatic Squamous Cell Carcinoma of the Cervix Presenting as an Adnexal Neoplasm
CON: Dose-dense Paclitaxel at 80 mg/m2 Weekly in Combination with Carboplatin AUC-6 Every Three Weeks Should Not be Considered Standard of Care in the Front Line Management of Ovarian Cancer
PRO: Dose-dense Paclitaxel in Combination with Carboplatin is an Acceptable Standard in the Front-Line Management of Advanced Stage Ovarian Cancer
The Prognostic Value of Syndecan-1 in Ovarian Cancer Patients with Long-Term Follow up
Clinical Ovarian … & Other Gynecologic Cancer Too!
PRO: Therapy for a Patient With Platinum–Resistant/Refractory Recurrent Ovarian Carcinoma Should be Selected Based on the Result of an In Vitro Chemoresistance Assay
CON: Therapy for a Patient With Platinum–Resistant/Refractory Ovarian Cancer Should Not be Selected Based on Results of an In Vitro Extreme Drug Sensitivity/Resistance Assay
PRO: Patients With Endometrial Carcinoma Involving Extrauterine Disease Should, After Any Indicated Surgery, Receive Chemotherapy
CON: Not All Patients With Endometrial Cancer With Extrauterine Disease Should Receive Chemotherapy After Any Indicated Surgery
PRO: Patients With Recurrent Ovarian Cancer Should be Treated With Antiangiogenic Agents in Combination With Chemotherapy
CON: Patients With Recurrent Ovarian Carcinoma Should Not be Treated With Antiangiogenic Agents in Combination With Chemotherapy
PRO: Secondary Surgical Debulking is an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
CON: Secondary Surgical Debulking is Not an Acceptable Option in Patients With Recurrent Platinum-Sensitive Ovarian Cancer
PRO: Patients at High Risk for Ovarian Cancer Should Undergo Routine Screening
CON: Patients at High Risk for Ovarian Cancer Should Not Undergo Routine Screening
PRO: Patients With Metastatic/Recurrent Cervical Cancer Should be Treated With Cisplatin Plus Paclitaxel
CON: Patients With Metastatic/Recurrent Cervical Cancer Should Not be Treated With Cisplatin Plus Paclitaxel
PRO: Systemic Therapy for All Endometrial Cancers Should be Paclitaxel Plus Carboplatin
CON: Systemic Therapy for All Endometrial Carcinomas Should Not be Paclitaxel Plus Carboplatin
PRO: All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment
CON: Not All Patients With Serous and Clear Cell Carcinomas of the Endometrium Should Receive Chemotherapy as Part of Their Treatment
Editorial Board
EUVIMED